Our novel ensilication technology exploits the growth of protective silica nanoshells on the surface of vaccine components, to prevent degradation, which can lead to vaccine spoilage.
Once applied, our vaccines can be stored and transported without the need for cold chain infrastructure, preventing wastage, improving shelf-life and increasing vaccine accessibility globally.
Ensilication can be applied to protect a wide variety of biomolecules against environmental degradation, eliminating the need for cold chain requirements and propelling the development of more oral and mucosal delivery of vaccines and therapeutics for both animals and humans.
We are actively looking for partners to work with us in developing new technologies free from the reliance on the cold chain. Please don't hesitate to contact us if you're interested in finding out more about us and the problem of cold chain dependent vaccines.
Company Details
- Employees
- 14
- Founded
- -
- Address
- Bristol, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ensilitech.com
- HQ
- Bristol
Ensilitech Questions
Ensilitech's website is http://www.ensilitech.com
Ensilitech's LinkedIn profile is https://uk.linkedin.com/company/ensilitech
Ensilitech has
14 employees.
View email and phone details for 14
employees at Ensilitech.
Ensilitech's industry is
Biotechnology Research
Ensilitech's top competitors are
Neuronostics,
Transdermal Diagnostics Ltd,
Lux Rewards,
Empirical Ventures,
Cytoseek,
Science Creates,
Nucleus Global, An Inizio Company,
Albotherm,
Extracellular,
Kelpi.
Ensilitech's categories are Biotechnology Research
Ensilitech's founding year is 2022
